Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.

Loading...
Thumbnail Image

Embargo End Date

Authors

Arce Vargas, F
Furness, AJS
Litchfield, K
Joshi, K
Rosenthal, R
Ghorani, E
Solomon, I
Lesko, MH
Ruef, N
Roddie, C
Henry, JY
Spain, L
Ben Aissa, A
Georgiou, A
Wong, YNS
Smith, M
Strauss, D
Hayes, A
Nicol, D
O'Brien, T
Mårtensson, L
Ljungars, A
Teige, I
Frendéus, B
TRACERx Melanoma,
TRACERx Renal,
TRACERx Lung consortia,
Pule, M
Marafioti, T
Gore, M
Larkin, J
Turajlic, S
Swanton, C
Peggs, KS
Quezada, SA

Document Type

Journal Article

Date

2018-04-09

Date Accepted

2018-02-15

Abstract

With the use of a mouse model expressing human Fc-gamma receptors (FcγRs), we demonstrated that antibodies with isotypes equivalent to ipilimumab and tremelimumab mediate intra-tumoral regulatory T (Treg) cell depletion in vivo, increasing the CD8+ to Treg cell ratio and promoting tumor rejection. Antibodies with improved FcγR binding profiles drove superior anti-tumor responses and survival. In patients with advanced melanoma, response to ipilimumab was associated with the CD16a-V158F high affinity polymorphism. Such activity only appeared relevant in the context of inflamed tumors, explaining the modest response rates observed in the clinical setting. Our data suggest that the activity of anti-CTLA-4 in inflamed tumors may be improved through enhancement of FcγR binding, whereas poorly infiltrated tumors will likely require combination approaches.

Citation

Cancer cell, 2018, 33 (4), pp. 649 - 663.e4

Source Title

Publisher

CELL PRESS

ISSN

1535-6108

eISSN

1878-3686

Research Team

Melanoma and Kidney Cancer
Sarcoma and Melanoma Surgery

Notes